LeAnne Kennedy

LeAnne Kennedy

Auto-generated profile, based on publicly available information

LeAnne Kennedy

Department of Pharmacy, Atrium Health Wake Forest Baptist, Winston Salem, NC, United States

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RWRebekah H Wrenn
Rebekah H Wrenn
ACAshley Cluck
Ashley Cluck
LKLeAnne Kennedy
LeAnne Kennedy
COChristopher Ohl
Christopher Ohl
JWJohn C Williamson
John C Williamson
Background: Extended infusion (EI) dosing provides a longer time above the minimum inhibitory concentration, which is important for the clinical success of β-lactam antibiotics, especially for patients with impaired immunity. The aim of this study was to determine the feasibility and clinical impact of administering cefepime by EI as treatment of febrile neutropenia. Methods: This was a prospective, randomized, comparative pilot study. All patients received cefepime 2 g IV every 8 h, with the first dose administered using a 30-min infusion. After the first dose, patients were randomized to receive cefepime over 30 min as a standard infusion (SI) or 3 h (EI). Patients were >18 years old with febrile neutropenia (neutrophil count 38.0ºC) and received chemotherapy or stem cell transplant as treatment for malignancy. Patients were excluded for the following: allergy to a cephalosporin, creatinine clearance (CrCl) < 50 mL/min, receipt of concurrent Gram-negative antimicrobial, sepsis, or solid tumor malignancy. The primary outcome was defervescence by 72 h. Secondary outcomes included time to defervescence, clinical success, in-hospital mortality, hospital length of stay, and need for additional antimicrobials. Main results: Sixty-three patients were enrolled: 33 in the SI arm and 30 in the EI arm. The groups were similar with regard to age, gender, weight, estimated creatinine clearance, and duration of neutropenia. None of the patients in the EI arm withdrew due to practical complications of receiving EI cefepime. Twenty-three patients in the SI arm and 20 patients in the EI arm defervesced by 72 h ( p = 0.99). There were no differences in secondary outcome measures; however, patients in the EI arm appeared to have defervesced more rapidly (median 19 vs. 41 h, p = 0.305). Conclusion: Administration of cefepime by EI for the treatment of febrile neutropenia is feasible. Larger clinical trials are necessary to determine if EI cefepime imparts a clinical benefit in the treatment of febrile neutropenia.

1 February 2011 in Journal of Blood Medicine
Verified
Journal Article
Open access
LKLeAnne Kennedy
LeAnne Kennedy
SKSuzannah Koontz
Suzannah Koontz
KRKamakshi Rao
Kamakshi Rao
Peer reviewed article authored by (LeAnne D Kennedy, Susannah Koontz, Kamakshi Rao). Read article or submit your manuscript for publishing.

1 February 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ZLZanetta S. Lamar
Zanetta S. Lamar
NFNora Fino
Nora Fino
JPJodi Palmer
Jodi Palmer
LGLindsey Gruber
Lindsey Gruber
BMBonny B. Morris
Bonny B. Morris
KZKenneth Zamkoff
Kenneth Zamkoff

28 October 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KSKaci Shuman
Kaci Shuman
SPShannon Palmer
Shannon Palmer
BABrandi Anders
Brandi Anders
DMDominic Moore
Dominic Moore
JPJonathan Ptachcinski
Jonathan Ptachcinski
JSJ. Ryan Shaw
J. Ryan Shaw
Single-agent, high-dose melphalan continues to be the most commonly used conditioning regimen for transplantation-eligible patients with multiple myeloma undergoing autologous stem cell transplantation. The timing of melphalan administration with respect to stem cell infusion has not been clearly defined. Many institutions require a minimum of 24 hours between melphalan administration and stem cell infusion; however, some institutions have adopted shorter intervals based on melphalan's short half-life. Some studies have suggested that shortening the interval between melphalan administration and stem cell infusion may contribute to delays in engraftment, but this correlation has not been clearly evaluated or defined. This multicenter retrospective cohort study evaluated the times to neutrophil and platelet engraftment in patients who received stem cells at least 24 hours after melphalan (≥24 hours cohort) compared with those who received stem cells within 24 hours of melphalan (<24 hours cohort. The study included a total of 723 adult patients, 502 patients in the ≥24 hours cohort and 221 in the <24 hours cohort, treated at 3 transplantation centers between January 1, 2016, and September 30, 2019. Patient characteristics were summarized using descriptive statistics. The Fisher exact test was used to compare nominal categorical variables between the 2 cohorts, and the nonparametric van der Waerden test or Mood median test was used to compare ordinal or continuous variables. The median time to neutrophil engraftment was 12 days for both the ≥24 hours cohort (interquartile range [IQR], 11 to 12 days) and the <24 hours cohort (IQR, 11 to 13 days) (P = .07). The median time to platelet engraftment was 19 days for both the ≥24 hours cohort (IQR, 17 to 22 days) and <24 hours cohort (IQR, 17 to 20 days) (P = .25). The median time between melphalan administration and stem cell infusion in the <24 hours cohort was 18 hours, with a minimum time of 12 hours. The existing literature has not clearly defined the impact of the timing between melphalan administration and stem cell infusion on engraftment in autologous transplantation. The ability to safely shorten the interval between chemotherapy and transplantation could increase logistical flexibility and/or decrease the length of hospital stay. This large multicenter retrospective study did not identify a statistical or clinical impact on engraftment when melphalan was infused <24 hours or ≥24 hours before autologous stem cell infusion.

8 May 2026 in Blood Advances
Verified
Journal Article
Open access
Wellington Fernandes SilvaWellington Fernandes Silva
Wellington Fernandes Silva
JYJun Yin
Jun Yin
MLMichaela Liedtke
Michaela Liedtke
DCDavid Claxton
David Claxton
NFNoreen Fulton
Noreen Fulton
WSWendy Stock
Wendy Stock

1 March 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MSMary Beth Seegars
Mary Beth Seegars
JTJanet Tooze
Janet Tooze
SIScott Isom
Scott Isom
BABrandi Anders
Brandi Anders
LKLeAnne Kennedy
LeAnne Kennedy
CRCesar Rodriguez
Cesar Rodriguez